KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook

KNSA Raises ARCALYST Sales View

Chief executive officer Sanj Patel said ARCALYST momentum supported raising 2026 net product revenue guidance to $980 million-$995 million from $930 million-$945 million.

Second-quarter ARCALYST revenue rose 55% year over year and increased by more than $29 million from the first quarter. Patel framed the gain as evidence of broader IL-1 pathway adoption in recurrent pericarditis.

Chief financial officer Mark Ragosa said operating income reached $27.2 million and net income was $25.4 million. Cash, cash equivalents and short-term investments totaled $525.9 million, with no debt.

Kiniksa Broadens the Prescribing Base

Chief operating officer Ross Moat attributed growth to gains in both new and repeat prescribing. About 450 health care professionals wrote their first ARCALYST prescription during the quarter, lifting the launch-to-date prescriber base above 5,000.

Roughly 150 additional prescribers moved into the repeat category from the first quarter. About 29% of the prescriber base has now written ARCALYST for two or more patients.

Moat also highlighted investments in machine learning, predictive alerts and the Heart’s Home direct-to-consumer campaign. He said dissemination of updated clinical guidance is helping physicians use ARCALYST earlier in the treatment sequence.

KNSA Advances KPL-387 Into Phase 3

Chief medical officer John Paolini said Phase 2 data supported selecting a 300-milligram monthly subcutaneous dose for the PASTORALE Phase 3 study.

Median time to treatment response and pain response was four days, while median time to C-reactive protein normalization was eight days. Paolini said efficacy remained durable across the monthly interval and tolerability was consistent with IL-1 pathway inhibition.

PASTORALE is enrolling up to about 85 participants in an event-driven randomized-withdrawal study. The primary endpoint is time to first adjudicated pericarditis recurrence, and management continues to target a 2028-2029 commercial launch.

Kiniksa Tests Monthly-Dose Appeal

A JPMorgan analyst asked whether the monthly KPL-387 profile could carry commercial significance. Chief operating officer Ross Moat cited prior market research showing about 75% of patients preferred the target profile over current commercial or investigational therapies.

Moat added that about 92% of health care professionals indicated a high likelihood of prescribing the product to new patients. Management also said another IL-1 therapy could expand the overall treated population.

A Wedbush analyst pressed for recurrence and follow-up details from the Phase 2 analysis. Chief Medical Officer John Paolini limited disclosure because the study remains ongoing, while emphasizing that 300-milligram monthly dosing maintained effect through the interval and biweekly dosing offered no incremental benefit.

KNSA Clarifies Demand and Gross-to-Net

A Citi analyst asked whether first-recurrence patients contributed to ARCALYST demand. Chief Operating Officer Ross Moat said about 80% of new prescriptions came from patients with two or more recurrences, while about 20% came from the larger first-recurrence group.

Management estimated that ARCALYST had reached about 21% of the 14,000-patient multiple-recurrence population. Chief executive officer Sanj Patel characterized that penetration level as evidence of remaining commercial runway.

In response to Wells Fargo, Chief Financial Officer Mark Ragosa said year-to-date gross-to-net was 7.2%, down from 8.6% in the first quarter, mainly because of lower co-pay support. He expects the usual pattern of lower rates in the middle quarters and some increase in the fourth quarter.

Kiniksa Keeps Focus on Execution

Management’s tone remained centered on disciplined commercial execution, continued patient penetration and timely delivery of KPL-387 milestones.

The company also kept KPL-1161 on track for a Phase 1 study by year-end 2026, extending its IL-1 franchise toward a targeted quarterly dosing profile.

KNSA’s Zacks Signals Remain Mixed

KNSA carries a Zacks Rank #3 (Hold). Its Growth, Momentum and VGM Scores are all A, indicating strong characteristics in those styles, while the Value Score of D points to a weaker valuation profile.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The combination is less favorable than a Zacks Rank #1 or #2 (Buy) paired with A or B Style Scores, but the strong Growth, Momentum and VGM grades remain relevant for investors using those styles. The Zacks Rank can change as earnings estimates are revised after the reported results.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research